The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Economic burden of seasonal influenza in the United States
Abstract
BACKGROUND Seasonal influenza is responsible for a large disease and economic burden. Despite the expanding recommendation of influenza vaccination, influenza has continued to be a major public health concern in the United States (U.S.). To evaluate influenza prevention strategies it is important that policy makers have current estimates of the economic burden of influenza. OBJECTIVE To provide an updated estimate of the average annual economic burden of seasonal influenza in the U.S. population in the presence of vaccination efforts. METHODS We evaluated estimates of age-specific influenza-attributable outcomes (ill-non medically attended, office-based outpatient visit, emergency department visits, hospitalizations and death) and associated productivity loss. Health outcome rates were applied to the 2015 U.S. population and multiplied by the relevant estimated unit costs for each outcome. We evaluated both direct healthcare costs and indirect costs (absenteeism from paid employment) reporting results from both a healthcare system and societal perspective. Results were presented in five age groups (<5 years, 5-17 years, 18-49 years, 50-64 years and ≥65 years of age). RESULTS The estimated average annual total economic burden of influenza to the healthcare system and society was $11.2 billion ($6.3-$25.3 billion). Direct medical costs were estimated to be $3.2 billion ($1.5-$11.7 billion) and indirect costs $8.0 billion ($4.8-$13.6 billion). These total costs were based on the estimated average numbers of (1) ill-non medically attended patients (21.6 million), (2) office-based outpatient visits (3.7 million), (3) emergency department visit (0.65 million) (4) hospitalizations (247.0 thousand), (5) deaths (36.3 thousand) and (6) days of productivity lost (20.1 million). CONCLUSIONS This study provides an updated estimate of the total economic burden of influenza in the U.S. Although we found a lower total cost than previously estimated, our results confirm that influenza is responsible for a substantial economic burden in the U.S.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Methods for the economic evaluation of health care programmes
Wilson, S. H. (1987) · Journal of Epidemiology and Community Health · doi:10.1136/jech.41.4.355-a · Cited by 4,275
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
The value of a statistical life: A critical review of market estimates throughout the world
Viscusi, W. K., & Aldy, J. E. (2003) · Journal of Risk and Uncertainty · doi:10.1023/a:1025598106257 · Cited by 2,135
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley, P. M., Weintraub, E., & Bridges, C. B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.046 · Cited by 1,722
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention
Meltzer, M. I., Cox, N. J., & Fukuda, K. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0505.990507 · Cited by 695
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
Zhou, H., Thompson, W. W., Viboud, C. G., Ringholz, C. M., Cheng, P.-Y., Steiner, C., Abedi, G. R., Anderson, L. J., Brammer, L., & Shay, D. K. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis211 · Cited by 573
Burden of Interpandemic Influenza in Children Younger than 5 Years: A 25‐Year Prospective Study
Neuzil, K. M., Zhu, Y., Griffin, M. R., Edwards, K. M., Thompson, J. M., Tollefson, S. J., & Wright, P. F. (2002) · The Journal of Infectious Diseases · doi:10.1086/338363 · Cited by 503
Cited by
Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E., & Monto, A. S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00982-5 · Cited by 560
The disease burden of influenza beyond respiratory illness
Macias, A. E., McElhaney, J. E., Chaves, S. S., Nealon, J., Nunes, M. C., Samson, S. I., Seet, B. T., Weinke, T., & Yu, H. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.09.048 · Cited by 371
A paradigm shift to combat indoor respiratory infection
Morawska, L., Allen, J., Bahnfleth, W., Bluyssen, P. M., Boerstra, A., Buonanno, G., Cao, J., Dancer, S. J., Floto, A., Franchimon, F., et al. (2021) · Science · doi:10.1126/science.abg2025 · Cited by 307
Immunization: vital progress, unfinished agenda
Piot, P., Larson, H. J., O’Brien, K. L., N’kengasong, J., Ng, E., Sow, S., & Kampmann, B. (2019) · Nature · doi:10.1038/s41586-019-1656-7 · Cited by 206
Phage display as a tool for vaccine and immunotherapy development
Hess, K. L., & Jewell, C. M. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10142 · Cited by 134
Metadata
- Authors
- Putri, W. C. W. S., Muscatello, D. J., Stockwell, M. S., & Newall, A. T.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 36
- Issue
- 27
- Pages
- 3960-3966
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2804447836
- Cited by
- 488
- References
- 35
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic burden of seasonal influenza in the United States. https://app.cochat.ai/papers/10.1016/j.vaccine.2018.05.057
- The paper
- Putri, W. C. W. S., Muscatello, D. J., Stockwell, M. S., & Newall, A. T. (2018). Economic burden of seasonal influenza in the United States. Vaccine. https://doi.org/10.1016/j.vaccine.2018.05.057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.